Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment? (Q38096472)

28 August 2017

Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment? (English)

1 reference

28 August 2017

1 reference

1

1 reference

28 August 2017

2

1 reference

28 August 2017

5

1 reference

28 August 2017

6

1 reference

28 August 2017

Paola Stiuso

8

0 references

Michele Caraglia

object named as

Michele Caraglia

11

0 references

Gerardo Botti

10

object named as

Gerardo Botti

1 reference

28 August 2017

3

Federica Zito Marino

1 reference

28 August 2017

Giuseppe Pirozzi

4

1 reference

28 August 2017

Pasquale Sperlongano

7

1 reference

28 August 2017

Amalia Luce

9

1 reference

28 August 2017

1 April 2013

1 reference

Expert Review of Anticancer Therapy

28 August 2017

1 reference

28 August 2017

13

1 reference

28 August 2017

407-420

1 reference

28 August 2017

4

1 reference

Anaplastic lymphoma kinase: signalling in development and disease

28 August 2017

1 reference

Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway

21 January 2018

1 reference

The anaplastic lymphoma kinase in the pathogenesis of cancer

21 January 2018

1 reference

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

21 January 2018

1 reference

Anaplastic lymphoma kinase in human cancer

21 January 2018

1 reference

Molecular pathogenesis of peripheral neuroblastic tumors

21 January 2018

1 reference

Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels.

21 January 2018

1 reference

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

Echinoderm microtubule-associated protein like protein 4, a member of the echinoderm microtubule-associated protein family, stabilizes microtubules

21 January 2018

1 reference

A mouse model for EML4-ALK-positive lung cancer

21 January 2018

1 reference

The biology and treatment of EML4-ALK non-small cell lung cancer

21 January 2018

1 reference

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

21 January 2018

1 reference

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

21 January 2018

1 reference

EML4-ALK: honing in on a new target in non-small-cell lung cancer.

21 January 2018

1 reference

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

21 January 2018

1 reference

Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity

21 January 2018

1 reference

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer

21 January 2018

1 reference

A novel KIF5B-ALK variant in nonsmall cell lung cancer.

21 January 2018

1 reference

KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only

21 January 2018

1 reference

Chromosomal and genomic changes in lung cancer

21 January 2018

1 reference

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

21 January 2018

1 reference

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer.

21 January 2018

1 reference

Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

21 January 2018

1 reference

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

21 January 2018

1 reference

Comprehensive histologic analysis of ALK-rearranged lung carcinomas

21 January 2018

1 reference

The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers

21 January 2018

1 reference

Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer

21 January 2018

1 reference

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.

21 January 2018

1 reference

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.

21 January 2018

1 reference

Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors.

21 January 2018

1 reference

Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene.

21 January 2018

1 reference

Treatment of lung cancer with an ALK inhibitor after EML4-ALK fusion gene detection using endobronchial ultrasound-guided transbronchial needle aspiration.

21 January 2018

1 reference

EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers

21 January 2018

1 reference

Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma.

21 January 2018

1 reference

Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.

21 January 2018

1 reference

EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.

21 January 2018

1 reference

Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

21 January 2018

1 reference

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry

21 January 2018

1 reference

Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.

21 January 2018

1 reference

Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression

21 January 2018

1 reference

Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.

21 January 2018

1 reference

Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers.

21 January 2018

1 reference

Biological role of anaplastic lymphoma kinase in neuroblastoma

21 January 2018

1 reference

Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer

21 January 2018

1 reference

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

21 January 2018

1 reference

Crizotinib in anaplastic large-cell lymphoma

21 January 2018

1 reference

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

21 January 2018

1 reference

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

21 January 2018

1 reference

ALK Inhibitors, a Pharmaceutical Perspective

21 January 2018

1 reference

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

Inhibitors of the anaplastic lymphoma kinase

21 January 2018

1 reference

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

21 January 2018

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon-alpha-mediated apoptosis in epidermoid cancer cells.

21 January 2018

1 reference

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond

21 January 2018

1 reference

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

21 January 2018

1 reference

GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers

21 January 2018

1 reference

Update in the treatment of brain metastases from lung cancer

21 January 2018

1 reference

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

21 January 2018

1 reference

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues

21 January 2018

1 reference

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

21 January 2018

1 reference

Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer

21 January 2018

1 reference

Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.

21 January 2018

1 reference

EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas

21 January 2018

1 reference

Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.13.18

1 reference

release_p5h5g3fxxjg4tjmrar57hcrc4u

28 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/p5h5g3fxxjg4tjmrar57hcrc4u

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference